Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition of angiostatin or its medicinal salt, and preparation method and use thereof

A technology for erlotinib and a composition, which is applied in the field of preparation of drugs for the treatment of hyperproliferative diseases, and can solve the problems of poor tolerance and inability to obtain satisfactory therapeutic effects and the like

Active Publication Date: 2014-11-12
JIANGSU HANSOH PHARMA CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While platinum-based first-line conventional chemotherapy regimens cannot achieve satisfactory therapeutic effects and are poorly tolerated, it is particularly urgent to research and develop a new type of effective and safe therapeutic drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of angiostatin or its medicinal salt, and preparation method and use thereof
  • Composition of angiostatin or its medicinal salt, and preparation method and use thereof
  • Composition of angiostatin or its medicinal salt, and preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Composition ingredients and dosage (1000 tablets):

[0028] active ingredient

[0029] Mix the prescribed amount of erlotinib hydrochloride, lactose, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate with a mixer, press into large pieces, and then crush the large pieces through 60 mesh screen. Collect the unscreened granules and add magnesium stearate, mix evenly, press into tablets, and spray the coating liquid on it to prepare film-coated tablets.

Embodiment 2

[0031] Composition ingredients and dosage (1000 tablets):

[0032] active ingredient

[0033] Mix the prescribed amount of erlotinib hydrochloride, pregelatinized starch, lactose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate with a mixer, press into large pieces, and then crush the large pieces through 60 mesh screen. Collect the unscreened granules and add magnesium stearate, mix evenly, press into tablets, and spray the coating liquid on it to prepare film-coated tablets.

Embodiment 3

[0035] Composition ingredients and dosage (1000 tablets):

[0036] active ingredient

[0037] pregelatinized starch

[0038] Mix the prescribed amount of erlotinib hydrochloride, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, poloxamer, and magnesium stearate with a mixer, press into large pieces, and then crush the large pieces through 60 Mesh sieve. Collect the unscreened granules and add magnesium stearate, mix evenly, press into tablets, and spray the coating liquid on it to prepare film-coated tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition of angiostatin or its medicinal salt, and a preparation method and a use thereof. The composition comprises 25-45wt% of angiostatin (a compound of formula I) or its pharmaceutically acceptable salt, and a medicinal excipient which can be used for treating over-proliferation diseases, such as cancers.

Description

technical field [0001] The invention relates to a composition containing erlotinib or a pharmaceutically acceptable salt thereof, a preparation method thereof and an application thereof in preparation of a medicine for treating hyperproliferative diseases. Background technique [0002] Erlotinib (also known as N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine), whether it is hydrochloride or methanesulfonic acid salt, are used in the treatment of hyperproliferative diseases such as cancer in mammals. [0003] Lung cancer is the most common malignant tumor in the world, and it is also the malignant tumor with the highest morbidity and mortality among urban residents in my country. With the influence of smoking and various environmental factors, the morbidity and mortality also show a continuous upward trend. In lung cancer, non-small cell lung cancer (Non-Small Cell Lung Cancer, NSCLC) accounts for about 80-85% of the total number of lung cancers. [0004] Non-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/517A61K47/36A61K47/34A61P35/00
Inventor 陈晶桂成龙刘晓枫郭延亮赵军军
Owner JIANGSU HANSOH PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com